Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[68Ga]B7H3 Affibody-BCH PET in Solid Tumors
NCT06454955Phase 1Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jan 2024
- Primary completion
- Nov 2024
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [68Ga]B7H3 Affibody-BCH in solid tumor, sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Standardized Uptake Value at 2 hours. Started Jan 2024; status: recruiting.
02
Drugs
[68Ga]B7H3 Affibody-BCH
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06454955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06454955.